UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder

American journal of transplantation, 2011-02, Vol.11 (2), p.336-347

2011

Volltextzugriff (PDF)

EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial

American journal of transplantation, 2008-05, Vol.8 (5), p.1016-1024

2008

Volltextzugriff (PDF)

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

Bone marrow transplantation (Basingstoke), 2009-03, Vol.43 (5), p.417-422

2009

Volltextzugriff (PDF)

Treatment of PTLD with Rituximab or Chemotherapy

American journal of transplantation, 2006-03, Vol.6 (3), p.569-576

2006

Volltextzugriff (PDF)

Post-transplant lymphoproliferative disorder: a review

Bone marrow transplantation (Basingstoke), 2003-02, Vol.31 (3), p.145-155

2003

Volltextzugriff (PDF)

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder

American journal of transplantation, 2015-10, Vol.15 (10), p.2665-2673

2015

Volltextzugriff (PDF)

Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders

American journal of transplantation, 2016-02, Vol.16 (2), p.379-380

2016

Volltextzugriff (PDF)

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

Bone marrow transplantation (Basingstoke), 2002-07, Vol.30 (1), p.23-28

2002

Volltextzugriff (PDF)

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Hematological oncology, 2023-06, Vol.41 (S2), p.758-759

2023

Volltextzugriff (PDF)

Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignancies

Hematological oncology, 2023-06, Vol.41 (S2), p.480-481

2023

Volltextzugriff (PDF)

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT

Hematological oncology, 2023-06, Vol.41 (S2), p.153-156

2023

Volltextzugriff (PDF)

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

Bone marrow transplantation (Basingstoke), 2005-12, Vol.36 (11), p.955-961

2005

Volltextzugriff (PDF)

Removal of gadolinium by peritoneal dialysis

Clinical nephrology, 2008-05, Vol.69 (5), p.368-373

2008

Volltextzugriff (PDF)

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Hematological oncology, 2021-06, Vol.39 (S2)

2021

Volltextzugriff (PDF)

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation

Bone marrow transplantation (Basingstoke), 2005-05, Vol.35 (9), p.921-926

2005

Volltextzugriff (PDF)

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY

HemaSphere, 2022-06, Vol.6, p.538-539

2022

Volltextzugriff (PDF)

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

Transplantation, 2001-04, Vol.71 (8), p.1076

2001

Volltextzugriff (PDF)

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S359-S360

2023

Volltextzugriff (PDF)

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S161

2023

Volltextzugriff (PDF)

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

Bone marrow transplantation (Basingstoke), 1999-09, Vol.24 (5), p.521-526

1999

Volltextzugriff (PDF)

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Hematological oncology, 2023-06, Vol.41, p.758-759

2023

Volltextzugriff (PDF)

In vitro Selection of an RNA Epitope Immunologically Cross-Reactive with a Peptide

Proceedings of the National Academy of Sciences - PNAS, 1992-10, Vol.89 (19), p.8864-8868

1992

Volltextzugriff (PDF)

In vitro selection of RNA epitopes using autoimmune patient serum

The Journal of immunology (1950), 1993-02, Vol.150 (3), p.1137-1145

1993

Volltextzugriff (PDF)

1 – 25 von 2.758

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(2.384)
Mit Volltextzugriff
(2.285)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.751)
Life Sciences & Biomedicine
(1.196)
Humans
(974)
Male
(600)
Female
(592)
Biological And Medical Sciences
(539)
Medical Sciences
(414)
Middle Aged
(405)
Animals
(372)
Adult
(366)
Physical Sciences
(341)
Aged
(275)
Technology
(271)
Physics
(268)
Mice
(168)
Fundamental And Applied Biological Sciences. Psychology
(158)
Exact Sciences And Technology
(140)
Biochemistry & Molecular Biology
(138)
Adolescent
(128)
Oncology
(125)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder

EBV PCR in the Diagnosis and Monitoring of Posttransplant Lymphoproliferative Disorder: Results of a Two‐Arm Prospective Trial

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

Treatment of PTLD with Rituximab or Chemotherapy

Post-transplant lymphoproliferative disorder: a review

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder

Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignancies

PIRTOBRUTINIB IN COVALENT BTK‐INHIBITOR PRE‐TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH >3 YEARS FOLLOW‐UP FROM START OF ENROLLMENT

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma

Removal of gadolinium by peritoneal dialysis

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIVE NON‐COVALENT BTK INHIBITOR IN PREVIOUSLY TREATED RICHTER TRANSFORMATION: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

P640: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON‐COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

In vitro Selection of an RNA Epitope Immunologically Cross-Reactive with a Peptide

In vitro selection of RNA epitopes using autoimmune patient serum

Suchergebnisse filtern